Thyrocare Technologies Q4 FY25 consolidated PAT up at Rs. 21.70 Cr
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
The 27 greenfield labs across the country ensure timely and accurate reporting
Phytonadione Injectable Emulsion possesses the same type and degree of activity as does naturally-occurring vitamin K
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed
Subscribe To Our Newsletter & Stay Updated